Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 39 - Medicinal preparations containing antigens or antibodies
Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
10/2003
10/22/2003EP1354599A2 Pharmaceutical or food composition for treating pathologies related to graft versus host
10/22/2003EP1354598A2 Therapeutic uses of BR43X2 soluble receptors
10/22/2003EP1354199A2 Diagnosis and treatment of multiple sclerosis
10/22/2003EP1354054A2 Polypeptides capable of binding to cd64 and comprising one or more heterologous t cell epitopes, and their uses
10/22/2003EP1354043A2 Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or virus resistance and their use as medicines
10/22/2003EP1354042A2 Proteins and nucleic acids encoding same
10/22/2003EP1354034A2 Transgenic transchromosomal rodents for making human antibodies
10/22/2003EP1353955A2 High affinity antibodies
10/22/2003EP1353951A1 Isolated human transporter protein, nucleic acid molecules encoding human transporter protein, and uses thereof
10/22/2003EP1353949A2 Compositions and methods relating to ovary specific genes and proteins
10/22/2003EP1353948A2 Soluble cyclic analogues of the beta amyloide peptide
10/22/2003EP1353940A2 Methods for producing and improving therapeutic potency of binding polypeptides
10/22/2003EP1353937A2 Specific human antibodies for selective cancer therapy
10/22/2003EP1353691A2 Molecular antigen array presenting amyloid beta
10/22/2003EP1353690A2 Non-glycosylated peptides derived from the rsv g protein and use thereof in a vaccine
10/22/2003EP1353689A2 Immunizing compositions and methods of use
10/22/2003EP1353688A2 Method and compositions for immunization with the pseudomonas v antigen
10/22/2003EP1353687A2 Methods for obtaining inhibitors of tirc7 ligand binding and uses thereof
10/22/2003EP1353686A2 Mhc class i associated peptides for prevention and treatment of tuberculosis
10/22/2003EP1353685A2 Controlled release pharmaceutical systems
10/22/2003EP1181371B1 Attenuated mutant enteropathogenic e. coli (epec) strains, process for their production and their use
10/22/2003EP0986572B1 Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
10/22/2003EP0948319B1 Encapsulated cells producing antibodies
10/22/2003EP0928136B1 Injectable compositions
10/22/2003EP0922059B1 Monoclonal antibodies that define unique meningococcal b epitopes and their use in the preparation of vaccine compositions
10/22/2003EP0851927B1 Compounds for immunotherapy and diagnosis of tuberculosis
10/22/2003CN1451046A 保守的奈瑟球菌抗原 Conservative Neisseria antigen
10/22/2003CN1451045A IFN-alpha homologues
10/22/2003CN1451043A Dual specificity antibodies and methods of making and using
10/22/2003CN1451042A Method of monitoring HIV drug resistance
10/22/2003CN1451038A Attenuated influenza virus useful as vaccine
10/22/2003CN1451015A Insect poison allergens with reduced LgE reactivity and method for producing the same
10/22/2003CN1450912A CD40 antagonists for use in treating psoriasis and other inflammatory skin conditions
10/22/2003CN1450911A New clinical parameters for determining hematologic toxicity proior to radioimmunotherapy
10/22/2003CN1450908A Neurotoxic oligomers
10/22/2003CN1450907A Beta glycan as an inhibin receptor and uses thereof
10/22/2003CN1450239A Emergency door opening system
10/22/2003CN1450164A Novel coronal virus strain and medicinal use thereof
10/22/2003CN1450086A Anti SARS specificity IgY and combination preparation thereof
10/22/2003CN1450084A Novel process for preparing recombinaant CHO cell hepatitis B vaccine
10/22/2003CN1449833A Human SARS immune globulin
10/22/2003CN1449832A Horse SARS-resisting serum
10/22/2003CN1449831A DNA vaccine pVPS2 for SARS virus
10/22/2003CN1449830A DNA vaccine pVFS for SARS virus
10/22/2003CN1449829A DNA vaccine pVPS for SARS virus
10/22/2003CN1449828A DNA vaccine pVPM for SARS virus
10/22/2003CN1449827A DNA vaccine pVPH for SARS virus
10/22/2003CN1449826A Gene vaccine for anti SARS coronal virus and use thereof
10/22/2003CN1449825A Method for inactivating Bordetella bronchiseptica culture, bacteria composition prepared by same and vaccine having same and use thereof
10/22/2003CN1449824A Process for preparing bacterial vaccine for aquiculture animal
10/22/2003CN1125174C Recombinant phages
10/22/2003CN1125083C Monoclonal antibody active against CD44V6
10/22/2003CN1124843C Stable glassy state powder formulations
10/22/2003CA2424577A1 Use of huntingtin and related compounds for modulating cell survival
10/21/2003US6635752 Diagnosis of Aids
10/21/2003US6635749 Auxotrophic attenuated strain of Listeria with a mutation in genes whose protein product is essential for growth used to elicit a t-cell immune response to an antigen
10/21/2003US6635746 Chlamydial vaccines and immunogenic compositions containing an outer membrane antigen and methods of preparation thereof
10/21/2003US6635745 Rapamycin assay
10/21/2003US6635744 Substantially pure fibroblast growth factor homologous factor-4 polypeptide having specified amino acid sequence; diagnosis and treatment of neurodegenerative and neoplastic disorders
10/21/2003US6635743 Isolated antibody or portion that binds to protein selected from those having specified amino acid sequences or fragments; control apoptosis for treatment of autoimmune disease, graft versus host disease, rheumatoid arthritis and lymphadenopathy
10/21/2003US6635624 Plasmid of partly bacterial origin; antibiotic resistance
10/21/2003US6635483 Antisense polynucleotide targeted to a nucleic acid encoding the gene, thereby suppressing its expression; cDNA encapsulated in liposome; use as antitumor, anticarcinogenic or antiapoptotic; Alzheimer's disease
10/21/2003US6635477 Comprising a open reading frame; use in diagnosis, treatment and prevention
10/21/2003US6635473 Isolated nucleic acid encoding a fibrinogen-binding protein; useful in prevention, diagnosis and treatment of infections; can be administered to wounds or for coating prosthetics to inhibit binding of the bacteria
10/21/2003US6635472 Polynucleotide constructs which can replicate episomally in vertebrate cells without integration into the chromosomal DNA of the host; reverse transcription; use in gene transfer, gene therapy and vaccines
10/21/2003US6635461 Encoded by isolated nucleic acid; has glycosyltransferase activity; given amino acid sequence; useful as diagnostic and therapeutic agent for cancer and thymus-related disorders
10/21/2003US6635449 Exonuclease-mediated nucleic acid reassembly in directed evolution
10/21/2003US6635431 Recombinant lipolysis stimulated (LSR) comprising polypeptide of given sequence; use for selecting a compound for enhancing lipoprotein uptake in cells expressing the polypeptide
10/21/2003US6635261 Adjuvant and vaccine compositions containing monophosphoryl lipid A
10/21/2003US6635258 Herpes simplex virus VP22 vaccines and methods of use
10/21/2003US6635257 Oligomeric particle having diameter of 1 to 100 nanometer and consisting of hepatitis C virus envelope proteins, or parts thereof, in which at least one cysteine is alkylated
10/21/2003US6635255 CASB414:antigen overexpressed in several tumors
10/21/2003US6635253 Composition for enhancing immunological effects
10/21/2003US6635251 Eotaxin-specific antibodies
10/21/2003US6635250 Use of certain metalloproteinase inhibitors for treating nerve disorders mediated by nucleus pulpsus
10/21/2003US6635249 Methods for treating congestive heart failure
10/21/2003US6635248 Isolated polypeptide consisting of single chain of amino acids comprising one or more penetrating fragments from one or more penetrating antibodies, which penetrates into cell
10/21/2003US6635246 Nasally or orally administering composition comprising influenza virus antigen obtained from mammalian cell culture comprising protein-free media, and aluminum salt, being free of media and egg proteins, to provoke immune response
10/21/2003CA2182289C Immuno-stimulatory monoclonal antibodies
10/21/2003CA2157659C Use of porcine gal .alpha. (1,3) galactosyl transferase in xenograft therapies
10/21/2003CA2156825C Inhibition of intimal hyperplasia using antibodies to pdgf receptors
10/21/2003CA2115049C Dna sequences encoding gelonin polypeptide
10/21/2003CA2106962C Polypeptides from mycobacterium paratuberculosis
10/21/2003CA2076432C Humanized antibody derivatives that recognize difucosyl lewis blood group antigens y-6 and b-7-2
10/21/2003CA2066940C Canine coronavirus subunit vaccine
10/21/2003CA2053924C Synthetic pseudomonas aeruginosa pilin peptide and related vaccines and diagnostics
10/21/2003CA2017166C Metalloproteinase inhibitor
10/16/2003WO2003085138A1 Methods of virus production
10/16/2003WO2003085134A2 Methods of diagnosing and treating colorectal cancer
10/16/2003WO2003085125A1 Use of biomolecular targets in the treatment and visualization of brain tumors
10/16/2003WO2003085119A1 METHOD OF ENHANCING ACTIVITY OF ANTIBODY COMPOSITION OF BINDING TO FcϜ RECEPTOR IIIa
10/16/2003WO2003085118A1 Process for producing antibody composition
10/16/2003WO2003085114A1 Method of designing synthetic nucleic acid sequences for optimal protein expression in a host cell
10/16/2003WO2003085098A2 Identification of virulence associated regions rd1 and rd5 enabling the development of improved vaccines of m. bovis bcg and m. microti
10/16/2003WO2003085090A2 A human ribonucleotide reductase m2 subunit
10/16/2003WO2003085089A2 Human monoclonal antibodies to interleukin-5 and methods and compositions comprising same
10/16/2003WO2003085087A2 Modified cea nucleic acid and expression vectors
10/16/2003WO2003085085A2 Superior molecular vaccine linking the translocation domain of a bacterial toxin to an antigen
10/16/2003WO2003084999A1 Induction of anti-tumor ctl immunity through in vivo triggering of 4-1bb and/or cd40
10/16/2003WO2003084996A2 Anti-idiotype anti-cea antibody molecules and its use as cancer vaccine
1 ... 1204 1205 1206 1207 1208 1209 1210 1211 1212 1213 1214 1215 1216 1217 1218 1219 1220 1221 1222 1223 1224 ... 1823